专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2542221A4 CONCENTRATED PROTEIN FORMULATIONS AND USES THEREOF 审中-公开
标题翻译：浓缩蛋白制剂及其用途
公开(公告)号：EP2542221A4
公开(公告)日：2013-10-23
申请号：EP11751179
申请日：2011-03-01
申请人： CYTODYN INC
发明人： CHEN TRACY T
IPC分类号： A61K9/08 , A61K9/00 , A61K39/395 , A61K47/18 , A61K47/26 , A61K47/48 , A61P31/18 , A61P35/00 , C07K16/00
CPC分类号： A61K9/0019 , A61K39/3955 , A61K47/183 , A61K47/26 , C07K16/00
摘要： Described are low viscosity, hypotonic formulations containing one or more proteins, e.g., antibodies, at high concentration, uses of the formulations, and articles of manufacture. In particular, the formulations are useful and beneficial for the subcutaneous administration or delivery of a high concentration of a protein drug, such as an antibody, to a subject who is afflicted with a disease or condition that is treatable by the protein drug.
摘要翻译：描述了含有一种或多种蛋白质的低粘度低渗制剂，例如高浓度的抗体，制剂的用途和制品。特别地，所述制剂对于可受到蛋白质药物可治疗的疾病或病症的受试者的皮下给药或递送高浓度的蛋白质药物如抗体是有用的和有益的。

2. 发明公开

EP3313412A1 INHIBITION OF CCL5 LIGAND BINDING TO CCR5 RECEPTOR AND ALTERATION OF CCR5/CCL5 AXIS SIGNALING IN INFLAMMATION, CANCER, AUTOIMMUNE, AND OTHER CONDITIONS 审中-公开
标题翻译： CCL5配体与CCR5受体结合的抑制作用及CCR5 / CCL5信号通路在炎症，癌症，自身免疫和其他疾病中的改变
公开(公告)号：EP3313412A1
公开(公告)日：2018-05-02
申请号：EP16815300.5
申请日：2016-06-23
申请人： CytoDyn Inc.
发明人： BURGER, Denis R.
IPC分类号： A61K31/7088 , A61K38/10 , A61K39/395
CPC分类号： A61K31/439 , A61K39/395 , A61K2039/505 , A61P25/28 , A61P31/12 , A61P37/06 , C07K16/2866 , C07K2317/76
摘要： Methods for the therapeutic use of competitive inhibitors of the CCR5/CCL5 axis that express antagonist activity for RANTES (CCL5) for immunomodulatory treatment of subjects in need thereof. The competitive inhibitors may not have CCL5 agonist activity and can be used to inhibit, interrupt, block, mitigate, slow the progress of, and/or treat inflammation and/or various other CCR5/CCL5 axis signaling dependent down-stream activities associated with transplantation, including graft versus host disease, autoimmune disorders, infectious agents, chronic inflammation, and cancer, etc.

3. 发明公开

EP1910573A2 METHODS FOR REDUCING VIRAL LOAD IN HIV-1-INFECTED PATIENTS 失效转让
标题翻译：一种用于减少病毒在最后加上HIV-1感染患者
公开(公告)号：EP1910573A2
公开(公告)日：2008-04-16
申请号：EP06788240.7
申请日：2006-07-21
申请人： PROGENICS PHARMACEUTICALS, INC.
发明人： OLSON, William, C. , MADDON, Paul, J. , PEVEAR, Daniel, C. , ISRAEL, Robert, J. , MURGA, Jose, D.
IPC分类号： C12Q1/68 , G01N33/53
CPC分类号： A61K39/39 , A61K31/351 , A61K31/4178 , A61K31/46 , A61K31/496 , A61K31/506 , A61K31/551 , A61K31/7072 , A61K38/1709 , A61K38/195 , A61K39/39541 , A61K39/3955 , A61K2039/505 , A61K2039/55511 , C07K16/2866 , C07K2317/24 , C07K2317/76 , C12Q1/701 , A61K2300/00
摘要： This method provides a method for reducing HIV-I viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-I viral load- reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-I -associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-I to CCR5+CD4+ target cells in the subject. This invention also provides a method for treating a subject infected with HIV-I comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4+ cells and (ii) inhibits fusion of HIV-I to the subject's CCR5+CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.

4. 发明授权

EP2721147B1 METHODS OF TREATING RETROVIRAL INFECTIONS IN FELINES 有权
标题翻译：治疗复发性恶性肿瘤的方法
公开(公告)号：EP2721147B1
公开(公告)日：2018-04-25
申请号：EP12799750.0
申请日：2012-06-15
申请人： CytoDyn, Inc.
发明人： TRAUGER, Richard
IPC分类号： C07K16/28 , A61K39/395 , A61P31/14
CPC分类号： A61K39/3955 , A61K31/341 , A61K31/366 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/443 , A61K31/4525 , C07K16/2845 , C07K2317/76 , C12N2740/15021
摘要： Provided are methods for treating or reducing the likelihood of developing a retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. These methods require the administration of at least one agent that specifically binds to CD11a and/or CD18, or ICAM-1, and/or decreases or prevents the binding of LFA-1 (CD11a/CD18 heterodimer) to ICAM-1. Also provided are veterinary compositions and methods of identifying candidate agents useful for treating or reducing retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline.

5. 发明公开

EP3107564A4 USE OF ANTI-CCR5 ANTIBODIES IN GRAFT VERSUS HOST DISEASE 审中-公开
标题翻译： VERWENDUNG VON ANTI-CCR5-ANTIKÖRPERBEI TRANSPLANTAT-GEGEN-WIRT-REAKTION
公开(公告)号：EP3107564A4
公开(公告)日：2017-08-30
申请号：EP15751704
申请日：2015-02-18
申请人： CYTODYN INC
发明人： MONTGOMERY ALAN B
IPC分类号： A61K39/00 , A61K39/395 , A61P29/00
CPC分类号： A61K39/3955 , A61K9/0019 , A61K9/0053 , A61K31/351 , A61K31/46 , A61K31/496 , A61K31/506 , A61K31/55 , A61K39/39541 , A61K45/06 , C07K16/2866 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： This composition and method provides for a method for reducing GVHD in a human subject which comprises administering to the subject at a predefined interval effective GVHD-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of GVHD. This invention also provides a method for treating a subject with GVHD comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4.sup.+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.
摘要翻译：该组合物和方法提供了用于减少人受试者中GVHD的方法，其包括以预定间隔对受试者施用有效GVHD减少剂量的（a）指定为PRO 140的人源化抗体或（b）抗CCR5 受体单克隆抗体。本发明还提供了用于抑制人受试者GVHD发作或进展的方法。本发明还提供了用于治疗患有GVHD的受试者的方法，其包括向受试者施用（a）单克隆抗体，其（i）与受试者的CD4 +细胞表面上的CCR5受体结合，和（b）非抗体CCR5受体拮抗剂，其量有效治疗受试者。

6. 发明公开

EP2983711A1 FELINIZED ANTIBODIES AND METHODS OF TREATING RETROVIRAL INFECTIONS IN FELINES 审中-公开
标题翻译： FELINESED抗体及治疗复发性感染的方法
公开(公告)号：EP2983711A1
公开(公告)日：2016-02-17
申请号：EP14783179.6
申请日：2014-04-08
申请人： CytoDyn Inc.
发明人： TRAUGER, Richard
IPC分类号： A61K39/395
CPC分类号： C07K16/2845 , A61K39/3955 , A61K45/06 , C07K2317/20 , C07K2317/24 , C07K2317/565 , C07K2317/76
摘要： Provided are felinized antibodies and methods for treating or reducing the likelihood of developing a retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. These methods require the administration of at least one felinized antibody or fragment thereof that specifically binds to CD11a and/or CD18, or ICAM-1, and/or decreases or prevents the binding of LFA-1 (CD11a/CD18 heterodimer) to ICAM-1. Also provided are veterinary compositions and methods of identifying candidate agents useful for treating or reducing retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline.
摘要翻译：提供了用于治疗或降低在猫科动物中发展逆转录病毒感染或减少逆转录病毒进入猫科动物细胞，减少来自猫科动物细胞的逆转录病毒病毒出芽，或减少猫科动物中的合胞体传播的可能性的猫科化抗体和方法。这些方法需要施用至少一种特异性结合CD11a和/或CD18或ICAM-1的猫源化抗体或其片段，和/或降低或防止LFA-1（CD11a / CD18异源二聚体）与ICAM- 1。还提供了鉴定用于治疗或减少猫科动物中的逆转录病毒感染，减少逆转录病毒进入猫科动物细胞，减少来自猫科动物细胞的逆转录病毒病毒出芽，或减少猫科动物中的合胞体传播的兽医组合物和方法。

7. 发明公开

EP2721147A4 METHODS OF TREATING RETROVIRAL INFECTIONS IN FELINES 有权
标题翻译： VERFAHREN ZUR BEHANDLUNG RETROVIRALER INFEKTIONEN BEI KATZEN
公开(公告)号：EP2721147A4
公开(公告)日：2015-12-09
申请号：EP12799750
申请日：2012-06-15
申请人： CYTODYN INC
发明人： TRAUGER RICHARD
IPC分类号： C12N5/16
CPC分类号： A61K39/3955 , A61K31/341 , A61K31/366 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/443 , A61K31/4525 , C07K16/2845 , C07K2317/76 , C12N2740/15021
摘要： Provided are methods for treating or reducing the likelihood of developing a retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. These methods require the administration of at least one agent that specifically binds to CD11a and/or CD18, or ICAM-1, and/or decreases or prevents the binding of LFA-1 (CD11a/CD18 heterodimer) to ICAM-1. Also provided are veterinary compositions and methods of identifying candidate agents useful for treating or reducing retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline.
摘要翻译：提供了用于治疗或减少在猫科动物中发生逆转录病毒感染的可能性的方法，减少逆转录病毒病毒体进入猫细胞，减少来自猫细胞的逆转录病毒病毒体出芽，或减少猫科动物中的合胞体传播。这些方法需要施用至少一种与CD11a和/或CD18或ICAM-1特异性结合的试剂，和/或降低或防止LFA-1（CD11a / CD18异二聚体）与ICAM-1的结合。还提供了兽医组合物和鉴定可用于治疗或减少猫科动物逆转录病毒感染的候选物质的方法，减少逆转录病毒病毒体进入猫细胞，减少来自猫科动物细胞的逆转录病毒病毒体芽出芽，或减少猫科动物中的合胞体传播。

8. 发明公开

EP3183270A4 HIV ANTIBODY THERAPY AS TREATMENT SUBSTITUTE 有权
公开(公告)号：EP3183270A4
公开(公告)日：2018-01-17
申请号：EP15832985
申请日：2015-08-20
申请人： CYTODYN INC
发明人： SCHOOLEY ROBERT T , POURHASSAN NADER Z
IPC分类号： C07K16/28 , A61K39/00
CPC分类号： C07K16/2866 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/76
摘要： This invention relates to the use of antibody therapy as a treatment substitute, or for treatment interruption, to treat HIV-1 infected patients. Specifically, the present invention relates to the use of antibody therapy, such as PRO 140 monoclonal anti-body therapy, as a monotherapy for treatment of HIV-1 infected patients.

9. 发明公开

EP3107564A1 USE OF ANTI-CCR5 ANTIBODIES IN GRAFT VERSUS HOST DISEASE 审中-公开
标题翻译： VERWENDUNG VON ANTI-CCR5-ANTIKÖRPERBEI TRANSPLANTAT-GEGEN-WIRT-REAKING
公开(公告)号：EP3107564A1
公开(公告)日：2016-12-28
申请号：EP15751704.6
申请日：2015-02-18
申请人： CytoDyn, Inc.
发明人： MONTGOMERY, Alan B.
IPC分类号： A61K39/00 , A61K39/395 , A61P29/00
CPC分类号： A61K39/3955 , A61K9/0019 , A61K9/0053 , A61K31/351 , A61K31/46 , A61K31/496 , A61K31/506 , A61K31/55 , A61K39/39541 , A61K45/06 , C07K16/2866 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： This composition and method provides for a method for reducing GVHD in a human subject which comprises administering to the subject at a predefined interval effective GVHD-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of GVHD. This invention also provides a method for treating a subject with GVHD comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4.sup.+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.
摘要翻译：该组合物和方法提供了用于减少人受试者中的GVHD的方法，其包括以预定间隔向受试者施用有效的GVHD减少剂量的（a）命名为PRO 140的人源化抗体或（b）抗CCR5 受体单克隆抗体。本发明还提供了抑制人受试者GVHD发病或进展的方法。本发明还提供用于治疗患有GVHD的受试者的方法，其包括向受试者施用（a）单克隆抗体，所述单克隆抗体（i）结合受试者的CD4 +细胞表面上的CCR5受体，和（b）非抗体CCR5受体拮抗剂，其量有效治疗受试者。

10. 发明公开

EP2721147A1 METHODS OF TREATING RETROVIRAL INFECTIONS IN FELINES 有权
标题翻译：法复古CATS治疗病毒感染
公开(公告)号：EP2721147A1
公开(公告)日：2014-04-23
申请号：EP12799750.0
申请日：2012-06-15
申请人： CytoDyn, Inc.
发明人： TRAUGER, Richard
IPC分类号： C12N5/16
CPC分类号： A61K39/3955 , A61K31/341 , A61K31/366 , A61K31/4025 , A61K31/426 , A61K31/427 , A61K31/443 , A61K31/4525 , C07K16/2845 , C07K2317/76 , C12N2740/15021
摘要： Provided are methods for treating or reducing the likelihood of developing a retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. These methods require the administration of at least one agent that specifically binds to CD11a and/or CD18, or ICAM-1, and/or decreases or prevents the binding of LFA-1 (CD11a/CD18 heterodimer) to ICAM-1. Also provided are veterinary compositions and methods of identifying candidate agents useful for treating or reducing retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式